Which statement about Schedule II stimulants is true?

Study for the Federal Requirements for PTCB Test. Master key topics with flashcards and challenging multiple-choice questions. Each question comes with hints and explanations to solidify your understanding. Prepare confidently for your certification exam!

Multiple Choice

Which statement about Schedule II stimulants is true?

Explanation:
Schedule II stimulants are drugs with a high potential for abuse but with accepted medical uses, which is reflected in their strict regulatory controls. The statement that includes amphetamine, methamphetamine, and methylphenidate is correct because these specific agents are listed in Schedule II and are prescribed for conditions like ADHD and narcolepsy, despite their abuse risks. The other ideas are not accurate: these medications are indeed used medically, so saying they aren’t used medically is false. Schedule II designation signals a real abuse potential, so claiming there is no potential for abuse is false. And while states may have additional rules, federal law requires a prescription for these substances nationwide, not only in a limited number of states; they aren’t restricted to a few states only.

Schedule II stimulants are drugs with a high potential for abuse but with accepted medical uses, which is reflected in their strict regulatory controls. The statement that includes amphetamine, methamphetamine, and methylphenidate is correct because these specific agents are listed in Schedule II and are prescribed for conditions like ADHD and narcolepsy, despite their abuse risks.

The other ideas are not accurate: these medications are indeed used medically, so saying they aren’t used medically is false. Schedule II designation signals a real abuse potential, so claiming there is no potential for abuse is false. And while states may have additional rules, federal law requires a prescription for these substances nationwide, not only in a limited number of states; they aren’t restricted to a few states only.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy